Detalles de la búsqueda
1.
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Genes Chromosomes Cancer
; 59(4): 225-239, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31705765
2.
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
J Urol
; 202(4): 732-741, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31216253
3.
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 120(5B): E30-E44, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27539393
4.
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
BMC Cancer
; 16(1): 744, 2016 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27658492
5.
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.
Int J Mol Sci
; 17(9)2016 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27618023
6.
ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.
Prostate
; 73(11): 1233-40, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23653096
7.
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
NPJ Precis Oncol
; 5(1): 76, 2021 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34385567
8.
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
Eur Urol Oncol
; 4(6): 1001-1005, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32417369
9.
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Clin Cancer Res
; 27(5): 1391-1398, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33262136
10.
Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Eur Urol
; 77(2): 170-177, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31648903
11.
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Clin Cancer Res
; 26(15): 4143-4153, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32341031
12.
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer.
Cancer Res
; 80(22): 4892-4903, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32816908
13.
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Mol Cancer Ther
; 19(5): 1157-1164, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32127465
14.
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Eur Urol
; 77(6): 701-710, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32165065
15.
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.
JCO Precis Oncol
; 32019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32832835
16.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Sci Transl Med
; 11(484)2019 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30894499
17.
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
J Clin Oncol
; 37(13): 1120-1129, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30865549
18.
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
JAMA Oncol
; 4(9): 1179-1186, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29955787
19.
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
JAMA Oncol
; 4(10): 1344-1351, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29978216
20.
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
J Immunother Cancer
; 6(1): 141, 2018 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514390